1 / 6

Clinical Trial of Sofosbuvir and Ribavirin for Hepatitis C

Explore results of Sofosbuvir and Ribavirin treatment in Hepatitis C patients, comparing treatment-naïve and experienced cases. The study includes various arms and dosing regimens over different durations to achieve sustained virologic response at 12 weeks post-treatment.

ailish
Download Presentation

Clinical Trial of Sofosbuvir and Ribavirin for Hepatitis C

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 2a Treatment Naïve and Treatment Experienced Sofosbuvirand Ribavirin +/- Peginterferon in GT 1-3ELECTRON Trial (Arms 1-8) Gane EJ, et al. N Engl J Med. 2013;368:34-44.

  2. Sofosbuvir and Ribavirin +/- Peginterferon in GT 1-3ELECTRON Trial (Arms 1-8): Features Source: Gane EJ, et al. N Engl J Med. 2013;368:34-44.

  3. Sofosbuvir and Ribavirin +/- Peginterferon in GT 1-3ELECTRON Trial (Arms 1-8): Design 0 8 12 20 24 Week SVR12 n =10 GT 2,3Naïve SOF + RBV SVR12 n = 9 SOF + RBV + PEG (week 1-4) SVR12 n = 10 SOF + RBV + PEG (week 1-8) SVR12 n = 11 SOF + RBV + PEG SVR12 n =10 SOF SVR12 n = 10 SOF + RBV + PEG SVR12 n = 10 GT 1 Null SOF + RBV SVR12 n = 25 GT 1 Naive SOF + RBV Drug DosingSofosbuvir (SOF): 400 mg once dailyRibavirin (RBV) weight-based and divided bid: 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kgPeginterferon alfa-2a (PEG): 180 µg once weekly N =14 Source: Gane EJ, et al. N Engl J Med. 2013;368:34-44.

  4. Sofosbuvir and Ribavirin +/- Peginterferon in GT 1-3ELECTRON Trial (Arms 1-8): Results ELECTRON: SVR 12, by Treatment Regimen 1/10 10/10 9/9 10/10 11/11 6/10 10/10 21/25 Exp-Null Naive Genotype 2 or 3 (all treatment naïve) Genotype 1 Source: Gane EJ, et al. N Engl J Med. 2013;368:34-44.

  5. Sofosbuvir + RBV in Treatment-Experienced HCV GT 2 or 3ELECTRON Trial (Arms 1-8): Conclusions Source:Gane EJ, et al. N Engl J Med. 2013;368:34-44.

  6. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related